The stock of Vascular Solutions, Inc. (NASDAQ:VASC) reached all time high today, Nov, 24 and still has $57.07 target or 5.00% above today’s $54.35 share price. This indicates more upside for the $944.97 million company. This technical setup was reported by Barchart.com. If the $57.07 PT is reached, the company will be worth $47.25M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. The stock increased 1.78% or $0.95 on November 23, hitting $54.35. About 59,946 shares traded hands. Vascular Solutions, Inc. (NASDAQ:VASC) has risen 44.93% since April 22, 2016 and is uptrending. It has outperformed by 39.52% the S&P500.
Analysts await Vascular Solutions, Inc. (NASDAQ:VASC) to report earnings on January, 19. They expect $0.34 EPS, up 3.03% or $0.01 from last year’s $0.33 per share. VASC’s profit will be $5.91M for 39.96 P/E if the $0.34 EPS becomes a reality. After $0.31 actual EPS reported by Vascular Solutions, Inc. for the previous quarter, Wall Street now forecasts 9.68% EPS growth.
Vascular Solutions, Inc. (NASDAQ:VASC) Ratings Coverage
Out of 3 analysts covering Vascular Solutions (NASDAQ:VASC), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Vascular Solutions has been the topic of 3 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Piper Jaffray maintained the shares of VASC in a report on Tuesday, August 11 with “Overweight” rating. The firm earned “Buy” rating on Thursday, October 6 by Needham.
According to Zacks Investment Research, “Vascular Solutions Inc. manufactures, markets and sells the Vascular Solutions Duett sealing device, which enables cardiologists and radiologists to rapidly seal the puncture site following catheterization procedures such as angiography, angioplasty and stenting. Its product combines a simple balloon catheter delivery mechanism with a powerful, proprietary procoagulant. The company believes its product offers advantages over both manual compression and the three other FDA-approved devices used to seal the puncture site following the catheterization.”
Insitutional Activity: The institutional sentiment increased to 1.2 in Q2 2016. Its up 0.01, from 1.19 in 2016Q1. The ratio improved, as 10 funds sold all Vascular Solutions, Inc. shares owned while 44 reduced positions. 15 funds bought stakes while 49 increased positions. They now own 14.00 million shares or 4.98% more from 13.33 million shares in 2016Q1.
Moreover, Blackrock Group Inc Limited has 0% invested in Vascular Solutions, Inc. (NASDAQ:VASC) for 17,600 shares. Parametric Portfolio Lc last reported 26,614 shares in the company. Granahan Inv Mngmt Ma owns 162,646 shares or 0.25% of their US portfolio. Waddell And Reed Financial Incorporated, a Kansas-based fund reported 135,521 shares. Us State Bank De accumulated 0% or 1,757 shares. Moreover, Strs Ohio has 0% invested in Vascular Solutions, Inc. (NASDAQ:VASC) for 15,500 shares. Manufacturers Life Insurance Com The holds 0% or 11,670 shares in its portfolio. The Ontario – Canada-based Royal Bancorp Of Canada has invested 0.02% in Vascular Solutions, Inc. (NASDAQ:VASC). Cap Impact Advsr Ltd Liability accumulated 29,709 shares or 0.58% of the stock. The Minnesota-based Mairs And Pwr has invested 0.04% in Vascular Solutions, Inc. (NASDAQ:VASC). Thompson Davis Comm last reported 0.14% of its portfolio in the stock. Guggenheim Capital Ltd Company holds 0.01% of its portfolio in Vascular Solutions, Inc. (NASDAQ:VASC) for 46,257 shares. Morgan Stanley last reported 0% of its portfolio in the stock. Arbor Cap Mngmt Ltd last reported 1.85% of its portfolio in the stock. Aqr Limited Com accumulated 20,711 shares or 0% of the stock.
Insider Transactions: Since July 27, 2016, the stock had 0 insider purchases, and 2 sales for $2.27 million net activity. 10,011 Vascular Solutions, Inc. (NASDAQ:VASC) shares with value of $463,109 were sold by RUTSTEIN WILLIAM. ROOT HOWARD also sold $1.80M worth of Vascular Solutions, Inc. (NASDAQ:VASC) on Wednesday, July 27.
Another recent and important Vascular Solutions, Inc. (NASDAQ:VASC) news was published by Startribune.com which published an article titled: “Vascular Solutions, CEO acquitted of federal charges in off-label case” on February 26, 2016.
VASC Company Profile
Vascular Solutions, Inc., incorporated on December 20, 1996, is a medical device firm focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world. The Company’s products include GuideLiner catheters, Pronto catheters, Vein catheter reprocessing, Micro-introducer kits, Hemostatic patches, Radial access products, Langston catheters and D-Stat Flowable hemostat. The Firm creates minimally invasive medical devices and then delivers these products and related services to physicians through its direct domestic sales force and its international distribution network.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.